Journal
NATURE GENETICS
Volume 35, Issue 4, Pages 367-371Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ng1270
Keywords
-
Categories
Funding
- Telethon [GP0229Y01, GGP02123] Funding Source: Medline
Ask authors/readers for more resources
Collagen VI is an extracellular matrix protein that forms a microfilamentous network in skeletal muscles and other organs(1-3). Inherited mutations in genes encoding collagen VI in humans cause two muscle diseases, Bethlem myopathy and Ullrich congenital muscular dystrophy(4,5). We previously generated collagen VI deficient (Col6a1(-/-)) mice and showed that they have a muscle phenotype that strongly resembles Bethlem myopathy(6). The pathophysiological defects and mechanisms leading to the myopathic disorder were not known. Here we show that Col6a1(-/-) muscles have a loss of contractile strength associated with ultrastructural alterations of sarcoplasmic reticulum (SR) and mitochondria and spontaneous apoptosis. We found a latent mitochondrial dysfunction in myofibers of Col6a1(-/-) mice on incubation with the selective F1FO-ATPase inhibitor oligomycin, which caused mitochondrial depolarization, Ca2+ deregulation and increased apoptosis. These defects were reversible, as they could be normalized by plating Col6a1(-/-) myofibers on collagen VI or by addition of cyclosporin A (CsA), the inhibitor of mitochondrial permeability transition pore (PTP). Treatment of Col6a1(-/-) mice with CsA rescued the muscle ultrastructural defects and markedly decreased the number of apoptotic nuclei in vivo. These findings indicate that collagen VI myopathies have an unexpected mitochondrial pathogenesis that could be exploited for therapeutic intervention.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available